drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (autologous CAR T-cell therapy)
drug_description
Patient-derived T lymphocytes genetically engineered to express a chimeric antigen receptor targeting B-cell antigens (e.g., CD19) for MHC-independent recognition and killing of malignant B cells via CD3ΞΆ and costimulatory domains (CD28 or 4-1BB); associated immune activation can lead to CRS and ICANS.
nci_thesaurus_concept_id
C200766
nci_thesaurus_definition
Autologous T-lymphocytes engineered to contain one or more chimeric antigen receptors (CARs) that specifically target one or more specific antigen(s).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor (e.g., anti-CD19) that recognizes B-cell antigens independently of MHC and signals via CD3zeta with CD28 or 4-1BB costimulation, activating cytotoxicity and cytokine release to eliminate malignant B cells (with risks of CRS and ICANS).
drug_name
Autologous CAR-T cells
nct_id_drug_ref
NCT06720701